Pacira | PCRX - Operating Expenses


Pacira reported $172.75M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Astellas Pharma JPY 489.36B 52.69B Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Cara Therapeutics USD 5.94M 983K Sep/2025
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 17.83B 388M Jun/2026
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novo Nordisk DKK 37.21B 9.56B Mar/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Xeris Pharmaceuticals USD 75.21M 6.18M Mar/2026
Xoma USD 22.84M 1.67M Sep/2024
Zoetis USD 3.23B 1.68B Mar/2026